GlassScriptPhysician profile
Jeena Mathew
NPI 1760988497
$2,809.73
in general payments reported to CMS, 2019-2025
38 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $32.31 · 2024: $758 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791 · Education: $18.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.89 |
| Education | $18.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $455.08 | 2024-2025 | Korlym |
| Novo Nordisk INC | $270.56 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $211.84 | 2024-2025 | Mounjaro, Zepbound, Taltz |
| Tandem Diabetes Care, INC. | $196.72 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $167.42 | 2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $150.44 | 2024-2025 | Evenity, Prolia, Repatha |
| Medtronic, INC. | $148.87 | 2025 | Symplicity G3 |
| Sanofi-Aventis U.S. LLC | $139.01 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.27 | 2024-2025 | Trintellix, Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $89.38 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $87.27 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $84.89 | 2025 | |
| Exact Sciences Corporation | $79.57 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.28 | 2025 | Caplyta |
| Lexicon Pharmaceuticals, INC. | $46.10 | 2024 | Inpefa |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $38.92 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $37.52 | 2025 | Capvaxive |
| Abbott Laboratories | $36.32 | 2024-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $35.94 | 2024 | Rexulti |
| Lundbeck LLC | $35.33 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $33.76 | 2024-2025 | Airsupra, Farxiga |
| Madrigal Pharmaceuticals | $32.07 | 2025 | Rezdiffra |
| Radius Health, INC. | $31.48 | 2025 | Tymlos |
| Mannkind Corporation | $30.51 | 2024 | |
| Depuy Synthes Sales INC. | $21.99 | 2024 | Orthovisc |
| Ucb, INC. | $19.19 | 2024 | Cimzia |
| Aimmune Therapeutics, INC. | $18.56 | 2025 | Zenpep |
| Djo, LLC | $17.90 | 2025 | Cmf |
| Alexion Pharmaceuticals, INC. | $17.79 | 2025 | Strensiq |
| Braintree Laboratories, INC. | $16.85 | 2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $16.69 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.29 | 2024 | Jardiance |
| Ironwood Pharmaceuticals, INC | $15.19 | 2024 | |
| Recordati_rare_diseases_inc. | $15.13 | 2024 | Signifor Lar, Isturisa |
| Celltrion USA INC. | $14.63 | 2024 | Zymfentra |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
| Bavarian Nordic A/S | $13.83 | 2025 | Vivotif |
| Cequr Corporation | $9.87 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeena Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.